Brown Advisory Inc. decreased its holdings in Baxter International Inc (NYSE:BAX) by 12.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 84,450 shares of the medical instruments supplier’s stock after selling 11,715 shares during the quarter. Brown Advisory Inc.’s holdings in Baxter International were worth $5,560,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Gantzert Investment Co. LLC ADV acquired a new stake in Baxter International during the fourth quarter valued at approximately $25,000. Parisi Gray Wealth Management acquired a new stake in Baxter International during the fourth quarter valued at approximately $26,000. Baldwin Brothers Inc. MA raised its stake in Baxter International by 904.0% during the fourth quarter. Baldwin Brothers Inc. MA now owns 502 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 452 shares in the last quarter. We Are One Seven LLC acquired a new stake in Baxter International during the fourth quarter valued at approximately $34,000. Finally, Financial Gravity Companies Inc. acquired a new stake in Baxter International during the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 81.39% of the company’s stock.
In related news, Director Thomas T. Stallkamp sold 1,638 shares of the stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $73.75, for a total value of $120,802.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John D. Forsyth sold 1,500 shares of the stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $75.92, for a total value of $113,880.00. Following the completion of the transaction, the director now directly owns 31,703 shares of the company’s stock, valued at $2,406,891.76. The disclosure for this sale can be found here. Insiders sold a total of 44,599 shares of company stock valued at $3,216,661 over the last three months. Corporate insiders own 0.07% of the company’s stock.
Several analysts have issued reports on BAX shares. Zacks Investment Research cut Baxter International from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. Morgan Stanley upped their price objective on Baxter International from $80.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, March 5th. Piper Jaffray Companies restated an “overweight” rating and set a $80.00 price objective on shares of Baxter International in a research note on Friday, February 1st. Wells Fargo & Co upped their price objective on Baxter International from $72.00 to $76.00 and gave the company an “outperform” rating in a research note on Tuesday, December 4th. Finally, UBS Group started coverage on Baxter International in a research note on Tuesday, November 27th. They set a “buy” rating and a $80.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the stock. Baxter International presently has a consensus rating of “Buy” and an average price target of $76.56.
NYSE:BAX opened at $76.94 on Friday. The company has a market cap of $39.43 billion, a PE ratio of 25.23, a P/E/G ratio of 1.90 and a beta of 1.00. Baxter International Inc has a 52 week low of $61.05 and a 52 week high of $78.38. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.09 and a quick ratio of 1.50.
Baxter International (NYSE:BAX) last posted its earnings results on Thursday, January 31st. The medical instruments supplier reported $0.78 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.05. Baxter International had a return on equity of 19.10% and a net margin of 14.60%. The company had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.80 billion. Equities research analysts anticipate that Baxter International Inc will post 3.27 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 1st. Investors of record on Friday, March 1st will be issued a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date is Thursday, February 28th. Baxter International’s dividend payout ratio (DPR) is 24.92%.
COPYRIGHT VIOLATION NOTICE: “Baxter International Inc (BAX) Position Lowered by Brown Advisory Inc.” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2019/03/17/baxter-international-inc-bax-position-lowered-by-brown-advisory-inc.html.
Baxter International Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.